Why Tevogen Bio Holdings Stock Is Moving Higher Today
Why Tevogen Bio Holdings Stock Is Moving Higher Today
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares are rising Monday after the company secured up to $50 million of financing from an existing investor.
週一，Tevogen Bio Holdings Inc.（納斯達克股票代碼：TVGN）股價上漲，此前該公司從現有投資者那裏獲得了高達5000萬美元的融資。
What Happened: After the market close on Friday, Tevogen announced that it entered into a binding term sheet agreement with an existing investor to secure up to $50 million of financing.
發生了什麼：週五收盤後，Tevogen宣佈與現有投資者簽訂了具有約束力的條款表協議，以獲得高達5000萬美元的融資。
The financing is aimed at supporting continued research and development efforts for Tevogen's TVGN 489. In addition, the financing will be utilized to start clinical trials for virally induced cancers and multiple sclerosis.
這筆資金旨在支持Tevogen的TVGN 489的持續研發工作。此外，這筆資金將用於啓動病毒誘發的癌症和多發性硬化症的臨床試驗。
"We strongly believe Tevogen's business model of efficient operations and innovative thinking allows us to meaningfully expand our R&D efforts and investments in Tevogen AI with the support of this additional financing. I'm pleased we are taking this significant step to help patients by providing affordable and accessible personalized T cell therapies for large patient populations." said Dr. Ryan Saadi, CEO of Tevogen.
“我們堅信，Tevogen的高效運營和創新思維的商業模式使我們能夠在這筆額外融資的支持下，有意義地擴大對Tevogen AI的研發工作和投資。我很高興我們正在採取這一重要步驟，通過爲大量患者群體提供負擔得起且可獲得的個性化T細胞療法來幫助患者。” Tevogen首席執行官瑞安·薩迪博士說。
Related Link: Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
相關鏈接：爲什麼JanOne股票交易價格上漲了19％；以下是20只股票，盤前走勢
The financing contains a $36 million line of credit from an existing investor and $14 million in private placement. The line of credit grants Tevogen access to $1 million per month at an interest rate of either the daily secured overnight financing rate plus 2% or 7% accruing quarterly, depending on which is lower.
該融資包含來自現有投資者的3,600萬美元信貸額度和1400萬美元的私募配售。信貸額度使Tevogen每月可獲得100萬美元的利率，利率爲每日有擔保隔夜融資利率加上2％或每季度應計7％，視哪個較低者而定。
"Our continued investment emphasizes our conviction in Tevogen, its leadership and novel technology. Tevogen's cost-effective business model and the promise of commercial success make this a compelling transaction," said investor Dr. Manmohan Patel, who is taking part in the financing transaction.
“我們的持續投資凸顯了我們對Tevogen、其領導地位和新技術的信念。參與融資交易的投資者曼莫漢·帕特爾博士說，Tevogen具有成本效益的商業模式和商業成功的前景使這筆交易成爲一項引人注目的交易。
Price Action: According to Benzinga Pro, Tevogen stock was trading 15.7% higher at $1.15 Monday morning.
價格走勢：根據Benzinga Pro的數據，週一上午Tevogen股價上漲15.7％，至1.15美元。
Image: 2616931 from Pixabay
圖片：來自 Pixabay 的 2616931
譯文內容由第三人軟體翻譯。